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The Controversies of Statin Therapy
Weighing the Evidence
J. Wouter Jukema, MD, PHD,*†‡ Christopher P. Cannon, MD,§ Anton J. M. de Craen, MSC, PHD,¶
Rudi G. J. Westendorp, MD, PHD,¶# Stella Trompet, MSC, PHD,*¶
Leiden, Amsterdam, and Utrecht, the Netherlands; and Boston, Massachusetts
The debate whether statins, 3-hydroxymethyl-3-methylglutaryl coenzyme A reductase inhibitors, are safe to use
has been raging since their introduction in 1987. Statins are generally well tolerated and are believed to have
minimal adverse effects. However, individual, specific rare adverse events have been reported, such as eleva-
tions of liver enzymes, muscle aches, and very rarely, rhabdomyolysis. Discontinuation and/or reduction in the
dose of the statin usually leads to resolution of these side effects. Recently, however, debate has focused on the
possible negative long-term effects of statin treatment on cognitive decline, the incidence of cancer, and the
development of diabetes mellitus. Recently, the U.S. Food and Drug Administration has expanded the warning
for statins with a statement that statin use may lead to cognitive impairment. In this review, we discuss all lev-
els of evidence, from case reports to large randomized controlled clinical trials, for the possible adverse effects
of statins on cognitive decline, cancer, and diabetes. After careful consideration of all discussed scientific evi-
dence, we conclude that there is no increased risk of cognitive decline or cancer with statin use. However, statin
use is related to a small increased risk of type 2 diabetes mellitus. In view of the overwhelming benefit of
statins in the reduction of cardiovascular events, we believe the small absolute risk for development of diabetes
is outweighed by the cardiovascular benefits in patients for whom statin therapy is recommended. We, there-
fore, suggest that clinical practice for statin therapy should not be changed on the basis of the most recent Food
and Drug Administration informational warnings. (J Am Coll Cardiol 2012;60:875–81) © 2012 by the
American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.07.007Cardiovascular disease is the leading cause of death in
industrialized countries (1). The prevention of cardiovascu-
lar disease is critically dependent on lipid-lowering therapy,
most often achieved with 3-hydroxymethyl-3-methylglutaryl co-
enzyme A (HMG-CoA) reductase inhibitors (statins). St-
atins are the most widely prescribed class of drugs world-
wide, and therapy leads to a reduction of cardiovascular
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accepted July 2, 2012.events by 25% to 45%. Statins are well tolerated and are
believed to have minimal adverse effects. Most common
adverse effects are myopathies, elevations of liver enzymes,
and very rarely, rhabdomyolysis. Discontinuation or reduc-
tion in the dose of statin treatment usually leads to resolu-
tion of these side effects. For many years, there has been
debate as to whether statins are indeed as safe as reported in
clinical trials (2). Most recently, the debate has centered on
whether use of statins causes cognitive decline, cancer,
and/or diabetes mellitus.
Recently, the U.S. Food and Drug Administration
(FDA) has expanded the warning section of the label for all
statins. The FDA concluded that serious liver injury with
statins is rare and unpredictable in individual patients, and
that routine periodic monitoring of liver enzymes does not
appear to be effective for detecting or preventing serious
liver injury. Therefore, labels were revised to remove the
need for routine periodic monitoring of liver enzymes.
However, the FDA also stated that statin use may
increase cognitive decline (3): “FDA has been investigating
reports of cognitive impairment from statin use for several
years. The agency has reviewed databases that record reports
of bad reactions to drugs and statin clinical trials that
included assessments of cognitive function. The reports about
memory loss, forgetfulness, and confusion span all statin
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Egan, Deputy Director for
Safety in FDA’s Division of Me-
tabolism and Endocrinology
Products, says these experiences
are rare but that those affected
often report feeling ‘fuzzy’ or un-
focused in their thinking. In gen-
eral, the symptoms were not se-
rious and were reversible within a
few weeks after the patient
stopped using the statin. Some
people affected in this way had been taking the medicine for
a day; others had been taking it for years.”
One might ask whether the warning of the FDA is
appropriate, and we wondered where the concern about the
safety of statins originates from. In this review paper, the
potential influence of statins on possible adverse effects is
discussed, with the focus on cognitive function, cancer, and
diabetes mellitus type 2, and is set into a broader perspective
based on the clinical and epidemiological evidence. We
therefore discuss the 3 possible adverse events—cognitive
function, cancer, and type 2 diabetes mellitus—according to
3 levels of evidence put forth to support the claims, namely,
case reports, observational studies, and randomized con-
trolled trials/systematic reviews of trials.
Case Reports
Cognition. The associations between statins and possible
adverse effects have been studied since the introduction of
statins in 1987 (4). Several case reports and case series have
suggested a potential negative association between statins
and cognitive function (5). Symptoms reported by patients
in these reports include short-term and long-term memory
loss, behavioral changes, impaired concentration and atten-
tion, paranoia, and anxiety. Because cholesterol synthesis is
essential for neurons to function normally, it is theoretically
possible that excessive inhibition of cholesterol synthetic
pathways may result in neurocognitive adverse effects.
In 2003, the FDA released information on 60 case reports
of memory loss associated with statins (5). The main
symptom related to statins in these reports was short-term
memory loss that occurred a few months after the start of
statin therapy or after a dosage increase. In half the case
reports, discontinuation of statin treatment resolved the
symptoms, suggesting a possible causal relationship. How-
ever, because many of these case reports were from consum-
ers and important data on medical history or other concom-
itant diseases or medication were missing, these findings
should be interpreted with great caution, and as such, this
information does not permit any firm conclusions regarding
causality (5). In general, the patient population receiving
statin therapy is already at risk for memory loss because of
cardiac risk factors, advancing age, and amyloidosis, which
Abbreviations
and Acronyms
CHD  coronary heart
disease
CI  confidence interval
FDA  Food and Drug
Administration
HRT  hormone
replacement therapy
OR  odds ratiocould lead to detection bias. Also, the absence of objectivememory tests and lipid data makes it difficult to causally link
the memory change to the lipid-lowering by statins.
Cancer and diabetes mellitus type 2. No formal case
reports of patients reporting incident cancer or incident
diabetes coinciding with statin therapy were found in our
review. Cancer and diabetes are both frequently occurring
long-term clinical outcomes and might therefore not be
linked to statin therapy in an individual patient.
Case reports are a valuable tool for signaling possible
adverse drug effects (6). However, a case report is hardly
ever definitive, and can rarely prove causation, although a
case report can suggest new hypotheses and stimulate
further study (7). Therefore, data from comparative studies
are necessary, either from observational studies or random-
ized trials.
Observational Research
Cognition. Many observational studies have investigated
the association between statin use and cognitive function
(4). We identified 9 observational studies that studied this
relationship (8–16). Four studies showed beneficial effects
of statins on cognitive performance (8–11), 3 studies found
no effect on cognitive function (12,15,16), and 2 studies
found an increased risk of cognitive impairment associated
with statin use (13,14). Given the heterogeneity of the
outcomes, the results of the observational studies are incon-
clusive. One of the main problems with investigating the
association between statin therapy and possible adverse
effects in observational studies is confounding by indication.
First, the patient population receiving statin therapy in
observational studies is already at risk for vascular disease,
has multiple cardiac risk factors, and is on average older
than those not receiving statin therapy. Therefore, these
subjects are by definition more prone to develop cognitive
impairment (17). Second, in observational studies a com-
parison is made between prevalent users of statins and
nonusers. That leads to another form of selection bias as
prevalent users have survived during their treatment period.
If treatment decreases the risk of a specific outcome, the
group of prevalent users will be enriched with susceptible
patients compared with the nonusers. Conversely, more
resilient patients will be in the user group if treatment
increases the risk of outcome (17). Statistical correction for
imbalances between treatment groups in observational stud-
ies has proven to be unreliable (18). An evident example of
such discrepancy is found in studies performed to analyze
the effect of postmenopausal hormone replacement therapy
(HRT) on coronary heart disease (CHD). Most observa-
tional studies found a lower risk of CHD in users of HRT
compared with nonusers, a finding that was interpreted as a
protective effect of HRT on CHD risk. However, a large
randomized clinical trial found a higher CHD risk among
incident users of HRT compared with placebo users (19).
Cancer. Numerous observational studies have reported an
association between low plasma cholesterol levels and higher
t
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September 4, 2012:875–81 Controversies of Statin Therapyrisk of cancer (20–25). That has led to concerns that
treatment with statins, which lower cholesterol levels, might
increase cancer risk. However, these observed associations
between low plasma cholesterol and increased risk of cancer
might originate from reverse causality or confounding. For
example, low plasma cholesterol levels might be caused by a
hypocholesterolemic effect of cancer in pre-clinical stages
(26). In that case, subjects with cancer would have an
abnormally low cholesterol level because of the cancer, not
vice versa (reverse causality). Furthermore, confounding
factors such as age, smoking, and alcohol use might also
explain some of the observed associations. Moreover, sub-
jects with low cholesterol may simply live long enough to
develop cancer.
To try to overcome the problems of reverse causality and
confounding, a Mendelian randomization study was per-
formed. Mendelian randomization is based on Mendel’s law
that inheritance of 1 genetic trait is independent of inher-
itance of other traits. We used the APOE genotype to assess
he association between cholesterol levels and cancer (27).
e found that subjects, when grouped by their baseline
holesterol levels, indeed had a higher cancer risk when their
aseline cholesterol levels were lower. However, when
ubjects were categorized according to their ApoE geno-
ypes, which also resulted in groups with significantly
ifferent cholesterol levels, no increased risk of cancer was
bserved in the group with low cholesterol levels (27). These
ndings suggest that low levels of cholesterol are not
ausally related to an increased risk of cancer—again show-
ng that results of observational studies are difficult to
nterpret with regard to causality.
ype 2 diabetes mellitus. The relation between statin
reatment and incident diabetes has not been described in
any observational studies. In a large observational study of
45,417 subjects, Sukhija et al. (28) found statin use to be
ssociated with higher fasting glucose levels. More recently,
he Women’s Health Initiative investigated this relation in
61,808 postmenopausal women ages 50 to 79 years (29).
tatin use at baseline was associated with a 1.7 higher risk of
ype 2 diabetes mellitus. This association remained after
djusting for potential confounders, and was observed for all
ypes of statins. However, this study had methodologic
imitations because the investigators could not adjust for
aseline cholesterol levels, which had been measured in only
0% of the participants. In addition, they did not analyze
ew users of statins and their risk, and the accuracy of the
iagnosis of incident diabetes was not optimal.
imitations of observational studies. Randomized clini-
al trials are usually the preferred strategy for obtaining
vidence on the effects of clinical interventions. Random-
zation prevents selection bias, which results in a similar
aseline prognosis for occurrence of the clinical outcome in
he treatment group and the placebo group. In observational
tudies, users have a different prognosis for the clinical
utcome compared to nonusers, as allocation of treatment
y clinicians is usually based on specific prognostic factors. tven rigorous adjustment for known prognostic factors does
ot result in unbiased estimates of treatment effects. On the
ontrary, the evidence on the safety of a clinical intervention
unintended effects) might be assessed by both observational
tudies and randomized trials. The drawback of assessing
he unintended effects in randomized trials is that they are
requently under-powered to find associations with adverse
utcomes and that their follow-up is often relatively short.
ssessing whether the unintended effects of a clinical
ntervention can be validly done from observational studies,
eing either case-control studies or prospective follow-up
tudies, depends on the judgment whether treated and
ntreated groups have a similar baseline prognosis for
evelopment of the adverse effect. Because treatment groups
ill frequently have similar baseline prognosis for the
dverse effect under study, observational research may yield
alid estimates (30,31). That is why observational studies
ften yield results similar to those of randomized controlled
rials for unintended effect of clinical interventions (32,33).
To investigate the relation between statins and adverse
vents like cognition, cancer, and diabetes, the use of
bservational studies may not be adequate because the
rognostic factors for the intended effects of statin treat-
ent (reduction of cardiovascular disease) are the same risk
actors for cognitive function (34,35), cancer (36,37), and
iabetes (38,39). Because the incidences of cognitive de-
line, cancer, and diabetes are relatively high among patients
or whom statin treatment is indicated, and follow-up of
atients in these trials is generally long enough for the
ossible adverse effects to occur (often 5 years), randomized
rials are the most appropriate design to assess whether
tatin treatment is associated with an increase of these
vents.
andomized Controlled Trials
nd Systematic Reviews
ognition. Two large randomized controlled clinical trials
ave examined the effect of statins on cognitive function as
he major secondary endpoint of the studies (40,41). First,
he PROSPER (Prospective Study of Pravastatin in the
lderly at Risk for Vascular Disease) investigated, in 5,804
articipants, the effect of pravastatin (40 mg daily) on
ognitive function, measured with an extensive set of vali-
ated tests for cognitive function (40). Every 9 months,
ognitive function was assessed, with a mean follow-up
eriod of 42 months. As expected over time, on average, a
eneral significant cognitive decline was indeed observed in
ll subjects, indicating that the measurements were appro-
riate. However, and most importantly, the decrease in
ognitive function over time was no different between
ravastatin treatment versus placebo (Fig. 1) (42). Also, no
dverse events such as memory loss or confusion were
eported to be more common with pravastatin use compared
o placebo.
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Study, investigated the effect of simvastatin (40 mg daily) on
cognitive function in 20,536 participants (41). Cognitive
function was assessed using the Telephone Interview for
Cognitive Status questionnaire. After a mean follow-up
period of 5.3 years, no significant change in cognitive
function was shown between simvastatin- and placebo-
treated patients (43). Because cognitive function after statin/
placebo therapy was measured only once at the end of the
study, the drop-out due to cognitive impairment during the
study could have biased the results. The JUPITER (Justifi-
cation for the Use of Statins in Primary Prevention: An
Intervention Trial Evaluating Rosuvastatin) study reported
no difference in cognitive function between rosuvastatin and
placebo users at the end of the trial; only a slight increase in
subjects reporting confusional state in the rosuvastatin
group was found (44). However, the JUPITER trial was not
designed to measure neurocognitive status in a systematic
way, so no definite conclusions can be drawn (44).
Twelve other small randomized controlled trials have
studied the relationship between statin use and cognitive
function as a primary outcome (45–56). The majority of the
trials, 9 studies, found no change in cognitive function
between statin and placebo users (45–49,51–53,55). One
Figure 1 Effect of Pravastatin on Cognitive Function Among Pa
The p values represent the statistical significance of the difference in test sco
PROSPER study. Means were assessed using linear mixed models adjusted for se
color-word test; (B) letter-digit coding test (LDCT); (C) picture learning test immed
Trompet et al. (42); permission for its use granted by the publisher.trial found a detrimental effect of statin use on cognitivefunction measured with the 4-word memory test (50). Two
studies found a benefit in cognitive function (54,56).
Taking all this evidence together from the randomized
controlled clinical trials, we believe that there is no evidence
to conclude that statins have detrimental (or beneficial)
effects on cognitive function. That does not exclude the
possibility that for an individual patient a rare side effect
may occur, as is the case for any other type of medication.
Cancer. As stated earlier, the discussion whether statins
might cause an increased risk of cancer has been ongoing
since the finding that low levels of low-density lipoprotein
cholesterol are associated with a higher risk of cancer
incidence. That raised the question whether lowering low-
density lipoprotein cholesterol levels with statin treatment
would increase risk of cancer. Cancer incidence has been
assessed in all large randomized controlled trials (57). Until
now, only 2 randomized controlled trials have reported an
increased risk of cancer in the statin group compared to the
placebo group. The PROSPER study found a 1.25 in-
creased risk for cancer incidence for the statin-treated
patients compared to the placebo group (40). Also, in the
LIPID (Long-Term Intervention With Pravastatin in Ische-
mic Disease) trial, an increased cancer risk in the pravastatin
group compared to placebo users was found when they
ants of the PROSPER Study
nges over time between statin users (squares) and nonusers (circles) in the
, educational status, country, and version of test where appropriate. (A) Stroop-
LTi); (D) picture learning test delayed (PLTd). Figure was originally published inrticip
re cha
x, age
iate (Panalyzed this in an elderly subgroup (58). Bonovos et al.
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effect of statin on cancer incidence. They pooled data from 12
large randomized controlled trials and found a nonsignificant
overall estimate of 1.07 (95% confidence interval [CI]: 0.97 to
1.18) with the random-effects model (Fig. 2). They also
Figure 2 Meta-Analysis of
Pravastatin Therapy and Cancer Risk
The risk ratios and 95% confidence intervals are displayed on a logarithmic
scale. Figure was originally published in Bonovas and Sitaras (60); permission
for its use granted by the publisher. © Canadian Medical Association. This
work is protected by copyright and the making of this copy was with the per-
mission of Access Copyright. Any alteration of its content or further copying in
any form whatsoever is strictly prohibited unless otherwise permitted by law.
Figure 3 Association Between Statin Therapy and Incident Dia
Events per 1,000 patient-years. Weights are from random-effects analysis. Figure
lisher. CI  confidence interval; OR  odds ratio.performed meta-regression to investigate the impact of age on
this association (60), and found that the risk ratios of cancer
associated with pravastatin therapy increased with advancing
age. The authors of the PROSPER study reported their
finding as a possible chance finding due to a skewed distribu-
tion of subjects with latent cancer (40). Now they have
extended their follow-up period by 10 years (from 3.5 to 14
years of follow-up) and found no increased risk of cancer
incidence for subjects treated with statins compared to placebo
(Prof. Ian Ford, personal communication, January 30, 2012).
Numerous other recent systematic reviews have also
shown no increased risk for cancer incidence with statin
treatment (2,33,57,61–65). The most recent meta-analysis
included 33 randomized controlled trials with data on first
incident cancers recorded after randomization (2). The
incidence of cancer was not different between statin groups
and control groups (3,706 [5.9%] vs. 3,746 [6.0%]; odds
ratio [OR]: 0.99, 95% CI: 0.94 to 1.04, p  0.69). In
conclusion, from all these systematic reviews and large
meta-analyses, we conclude that there is no increased risk of
incident cancer with statin treatment.
Type 2 diabetes mellitus. Researchers of large randomized
controlled trials have reported conflicting results about the
development of type 2 diabetes mellitus after receiving statin
therapy (66). For example, the JUPITER trial reported an
increased incidence of diabetes in the rosuvastatin group
compared to the placebo group (67), whereas the WOSCOPS
(West of Scotland Coronary Prevention Study) trial had
reported that pravastatin appeared to reduce the risk of
diabetes (68). A large meta-analysis was performed to
in 13 Major Cardiovascular Trials
iginally published in Sattar et al. (66); permission for its use granted by the pub-betes
was or
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systematically (66). Thirteen statin trials involving a total of
91,140 participants were identified that investigated this
association. Statin therapy was associated with a 9% in-
creased risk for incident diabetes (OR: 1.09; 95% CI: 1.02
to 1.17), as shown in Figure 3. There was, however, of
course a benefit in a reduction in CHD death, myocardial
infarction, and stroke. Meta-regression showed a stronger
association in trials with older participants. As such, there
was no apparent increased risk in trials in which patients
were on average age 60 years or younger (64). Conversely,
the risk was present in the older population, a group for
which the absolute benefit of statin therapy would also be
greater (66). Therefore, benefit was seen to outweigh risk,
especially for younger patients, for whom no increased risk
was apparent in this study.
Another recent meta-analysis showed that use of
intensive-dose statin therapy compared with moderate-dose
statin therapy led to a higher incidence of new-onset
diabetes (OR: 1.12, 95% CI: 1.04 to 1.22) (69). To put this
into a clinical perspective, intensive-dose statin therapy also
led to fewer major cardiovascular events compared to
moderate-dose statin therapy (OR: 0.84, 95% CI: 0.75 to
0.94) (69). Therefore, the large benefit of statins for
cardiovascular events outweighs the small absolute risk for
development of diabetes.
A potential mechanism to explain the findings of the
higher incidence with statin therapy has not yet been
identified. One possibility might be that statins directly
affect muscle or insulin action, resulting in higher diabetes
incidence. Animal models have shown that statin-induced
myopathy is associated with the development of muscle
insulin resistance (70). However, more research is needed to
provide more information regarding the underlying mech-
anism of the small statin-related diabetes risk.
Conclusions
Recent large meta-analyses and systematic reviews have
shown no convincing evidence for change in cognitive
function or risk of cancer after statin use. However, a
small increased risk for incident type 2 diabetes mellitus
has been observed. In view of the overwhelming benefit
of statins for reduction of cardiovascular events by 25% to
45%, the small increase in relative risk for the develop-
ment of diabetes is outweighed by the cardiovascular
benefit in the short and medium term for patients for
whom statin therapy is recommended. We, therefore,
suggest that clinical practice for statin therapy should not
be changed for patients with high cardiovascular risk or
existing cardiovascular disease. However, the newly iden-
tified diabetes risk should be taken into account if statin
therapy is considered for patients at low cardiovascular
risk or for patient groups for which cardiovascular benefit
has not been proven.Reprint requests and correspondence: Prof. J. Wouter Jukema,
Department of Cardiology, Leiden University Medical Center,
P.O. Box 9600, Leiden 2300 RC, the Netherlands. E-mail:
j.w.jukema@lumc.nl.
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